Accès ouvert
2021
article
OpenAlex
Brandon Essink, Charu Sabharwal, Kevin Cannon, Robert W. Frenck et autres
BACKGROUND: Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumococcal disease, but disease from non-PCV serotypes remains. The safety, tolerability, and immunogenicity of a 20-valent PCV (PCV20) were evaluated. METHODS: This pivotal phase 3, randomized, double-blind study enrolled adults into 3 age groups …
us
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Brandon Essink, James T. Peterson, Kari Yacisin, Himal Lal et autres
Pneumococcal disease can be serious and debilitating in older adults. Pneumococcal conjugate vaccines (PCVs), such as the 13-valent PCV (PCV13), reduce pneumococcal disease rates caused by vaccine serotypes. Development of PCVs offering additional coverage against serotypes not contained in PCV13 can reduce …
us
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Ana Strezova, Himal Lal, Igwebuike Enweonye, Laura Cámpora et autres
BACKGROUND: This study evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) and the reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine (Tdap) when co-administered in adults aged ≥50 years. METHODS: In this open label, multi-center study (NCT02052596), participants were randomized 1:1 to the …
be, us, nl
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Lidia Oostvogels, Thomas C. Heineman, Robert W. Johnson, Myron J. Levin et autres
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ).Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to receive 2 doses of RZV or placebo 2 months apart. …
be, gb, us, ca, cz, es, tw, jp, se, br, au
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Marta López‐Fauqued, Laura Cámpora, Frédérique Delannois, Mohamed El Idrissi et autres
BACKGROUND: The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies. METHODS: …
be, ch, au, es, us, ca, fi, br, mx, se, cz, de, it, jp, tw, Sénégal, rs
(code pays fourni par la source)
Accès ouvert
2019
erratum
OpenAlex
Céline Maréchal, Himal Lal, Airi Põder, Murdo Ferguson et autres
The authors regret an error in the footnote of Table 2: the adjusted GMC values were not only adjusted for baseline value, but also for age.The authors would like to
be, nl, ee
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Tomáš Mrkvan, Laura Cámpora, Grégory Catteau, Martine Douha et autres
Herpes zoster (HZ), caused by reactivation of varicella-zoster virus (VZV), typically manifests as a dermatomal rash and can result in complications, such as postherpetic neuralgia. HZ risk increases with age due to age-related decline of immunity. At time of study start, Zoster …
be, us, de
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Desmond Curran, Lidia Oostvogels, Thomas C. Heineman, Sean Matthews et autres
BACKGROUND: To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life. METHODS: The assessments were integrated in …
be, ca, es, us, au, se, cn, it, gb
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Céline Maréchal, Himal Lal, Airi Põder, Murdo Ferguson et autres
BACKGROUND: This study evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) when the first dose was co-administered with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged ≥50 years. METHODS: In this open label, multi-center study (NCT02045836), participants were …
be, us, ee, ca, nl
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Anthony L. Cunningham, Thomas C. Heineman, Himal Lal, Olivier Godeaux et autres
Background: The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods: Participants (ZOE-50: ≥50; …
au, be, cz, tw, ca, fi, us, kr, de, se, br
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Tino F. Schwarz, Stéphanie Volpe, Grégory Catteau, Roman Chlíbek et autres
BACKGROUND: Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least six years. We assessed immunogenicity nine years post-initial vaccination. METHODS: This open extension study (NCT02735915) followed 70 participants who received two HZ/su doses in the initial trial (NCT00434577). Blood …
de, be, cz, nl, us, se
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Martina Kovac, Himal Lal, Anthony L. Cunningham, Myron J. Levin et autres
BACKGROUND: An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70 years (ZOE-50 and ZOE-70, respectively). METHODS: Data from ZOE-50 and ZOE-70 trials …
us, au, gb, be, it
(code pays fourni par la source)